Annovis Bio Inc. (ANVS) NEW YORK STOCK EXCHANGE INC.

$11.90 (0.13) (-1.08%)

Market Cap: $127.28M

As of 03/28/24 04:00 PM EDT. Market closed.

(ANVS)

Annovis Bio Inc. (ANVS)
NEW YORK STOCK EXCHANGE INC.

$11.90
(0.13) (-1.08%)

Market Cap: $127.28M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after ... read more

annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Maria Maccecchini
Full Time Employees
8
URL
Address
1055 Westlakes Dr Ste 300, Pennsylvania, Berwyn, 19312-2410.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Maria Maccecchini
Full Time Employees
8
Address
1055 Westlakes Dr Ste 300, Pennsylvania, Berwyn, 19312-2410.
PRICE CHART FOR ANNOVIS BIO INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$12.07
Previous Close
$12.03
Days Range
$11.59 - $12.30
52 week range
$5.42 - $22.49
Volume
249,607
Avg. Volume (30 days)
263,556
Market Cap
$127.28M
Dividend Yield
-
P/E
-
Shares Outstanding
10,579,933
Open
$12.07
Previous Close
$12.03
Days Range
$11.59 - $12.30
52 week range
$5.42 - $22.49
Volume
249,607
Avg. Volume (30 days)
263,556
Market Cap
$127.28M
Dividend Yield
-
P/E
-
Shares Outstanding
10,579,933
FINANCIAL STATEMENTS FOR ANNOVIS BIO INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ANNOVIS BIO INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
White Mark K.DirectorNov 20, 2023 Option Exercise$6.101,99012,13961,167Nov 22, 2023, 04:27 PM
Hoffman Michael BDirectorNov 20, 2023 Option Exercise$6.10163,880999,668223,357Nov 22, 2023, 04:24 PM
Maccecchini Maria-LuisaPresident and CEONov 20, 2023 Option Exercise$6.1040,970249,9171,098,459Nov 22, 2023, 04:23 PM
Hagopian Henry IIIChief Financial OfficerNov 20, 2023 Option Exercise$6.108205,0021,820Nov 22, 2023, 04:21 PM
McCarthy ReidDirectorNov 20, 2023 Option Exercise$6.078245,0028,129Nov 21, 2023, 02:33 PM
Hoffman Michael BDirectorNov 20, 2023 Option Exercise$6.07164,7451,000,002224,222Nov 21, 2023, 02:32 PM
White Mark K.DirectorNov 20, 2023 Option Exercise$6.072,00012,14061,177Nov 21, 2023, 02:31 PM
Maccecchini Maria-LuisaPresident and CEONov 20, 2023 Option Exercise$6.0741,186249,9991,098,675Nov 21, 2023, 02:30 PM
Hagopian Henry IIIChief Financial OfficerNov 20, 2023 Option Exercise$6.078245,0021,824Nov 21, 2023, 02:29 PM
Bruck ClaudineDirectorNov 20, 2023 Option Exercise$6.071,0006,0707,567Nov 21, 2023, 02:27 PM
White Mark K.DirectorApr 07, 2023 Option Exercise$12.613,00037,83059,177Apr 11, 2023, 09:14 PM
Bruck ClaudineDirectorApr 07, 2023 Option Exercise$12.615006,3056,567Apr 11, 2023, 09:11 PM
Hagopian Henry IIIChief Financial OfficerApr 07, 2023 Option Exercise$12.611,00012,6101,000Apr 11, 2023, 09:08 PM
Hoffman Michael BDirectorApr 07, 2023 Option Exercise$12.6159,477750,00559,477Apr 11, 2023, 09:06 PM
McCarthy ReidDirectorApr 07, 2023 Option Exercise$12.614766,0027,305Apr 11, 2023, 09:05 PM
Maccecchini Maria-LuisaPresident and CEOApr 07, 2023 Option Exercise$12.6120,000252,2001,060,489Apr 11, 2023, 09:03 PM
Maccecchini Maria-LuisaPresident and CEOFeb 06, 2023 Option Exercise$0.1452,7557,3861,040,489Feb 08, 2023, 05:11 PM
Maccecchini Maria-LuisaPresident and CEOJan 14, 2022 Option Exercise$0.1432,9594,614987,734Jan 18, 2022, 09:08 PM
Hoffman Michael BDirectorJan 04, 2022 Option Exercise$19.786,748133,4751,416,283Jan 05, 2022, 07:41 PM
Hoffman Michael BDirectorJan 04, 2022 Option Exercise$3.5937,142133,4851,416,373Jan 05, 2022, 07:41 PM
Bruck ClaudineDirectorOct 11, 2021 Buy$27.661815,0066,067Oct 13, 2021, 04:03 PM
White Mark K.DirectorOct 12, 2021 Buy$27.405,000137,00056,177Oct 13, 2021, 04:02 PM
Maccecchini Maria-LuisaPRESIDENT AND CEOOct 11, 2021 Buy$27.6118,000496,980976,775Oct 13, 2021, 04:00 PM
McCarthy ReidDirectorAug 19, 2021 Buy$37.6150018,8056,829Aug 23, 2021, 11:36 AM
Hoffman Michael BDirectorJan 31, 2020 Option Exercise$4.8055,884268,2431,400,175Feb 05, 2020, 06:05 AM
Hoffman Michael BDirectorJan 31, 2020 Buy$6.0033,333199,99847,619Feb 05, 2020, 06:05 AM
Whelan, Jr. Robert M.DirectorJan 31, 2020 Option Exercise$4.8011,17653,64595,700Feb 05, 2020, 06:05 AM
Whelan, Jr. Robert M.DirectorJan 31, 2020 Buy$6.0025,000150,00025,000Feb 05, 2020, 06:05 AM
Bruck ClaudineDirectorJan 31, 2020 Option Exercise$4.801,1175,3625,886Feb 05, 2020, 06:04 AM
Bruck ClaudineDirectorJan 31, 2020 Buy$6.008004,800800Feb 05, 2020, 06:04 AM
Maccecchini Maria-LuisaPresident and CEOJan 31, 2020 Buy$6.001,6009,600207,942Feb 05, 2020, 06:03 AM
McGroarty Jeffrey BrianChief Financial OfficerFeb 03, 2020 Buy$7.1519,500139,42852,833Feb 05, 2020, 06:03 AM
McGroarty Jeffrey BrianChief Financial OfficerJan 31, 2020 Buy$6.0033,333199,99833,333Feb 05, 2020, 06:03 AM
White Mark K.DirectorJan 31, 2020 Option Exercise$4.803,25215,61051,177Feb 05, 2020, 06:02 AM
White Mark K.DirectorJan 31, 2020 Buy$6.001,73410,4041,734Feb 05, 2020, 06:02 AM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
White Mark K.Director11/20/202312,139
Hoffman Michael BDirector11/20/2023999,668
Maccecchini Maria-LuisaPresident and CEO11/20/2023249,917
Hagopian Henry IIIChief Financial Officer11/20/20235,002
McCarthy ReidDirector11/20/20235,002
Hoffman Michael BDirector11/20/20231,000,002
White Mark K.Director11/20/202312,140
Maccecchini Maria-LuisaPresident and CEO11/20/2023249,999
Hagopian Henry IIIChief Financial Officer11/20/20235,002
Bruck ClaudineDirector11/20/20236,070
White Mark K.Director04/07/202337,830
Bruck ClaudineDirector04/07/20236,305
Hagopian Henry IIIChief Financial Officer04/07/202312,610
Hoffman Michael BDirector04/07/2023750,005
McCarthy ReidDirector04/07/20236,002
Maccecchini Maria-LuisaPresident and CEO04/07/2023252,200
Maccecchini Maria-LuisaPresident and CEO02/06/20237,386
Maccecchini Maria-LuisaPresident and CEO01/14/20224,614
Hoffman Michael BDirector01/04/2022133,475
Hoffman Michael BDirector01/04/2022133,485
Bruck ClaudineDirector10/11/20215,006
White Mark K.Director10/12/2021137,000
Maccecchini Maria-LuisaPRESIDENT AND CEO10/11/2021496,980
McCarthy ReidDirector08/19/202118,805
Hoffman Michael BDirector01/31/2020268,243
Hoffman Michael BDirector01/31/2020199,998
Whelan, Jr. Robert M.Director01/31/202053,645
Whelan, Jr. Robert M.Director01/31/2020150,000
Bruck ClaudineDirector01/31/20205,362
Bruck ClaudineDirector01/31/20204,800
Maccecchini Maria-LuisaPresident and CEO01/31/20209,600
McGroarty Jeffrey BrianChief Financial Officer02/03/2020139,428
McGroarty Jeffrey BrianChief Financial Officer01/31/2020199,998
White Mark K.Director01/31/202015,610
White Mark K.Director01/31/202010,404
Load More Insider Transactions
FUNDS WITH A POSITION IN ANNOVIS BIO INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ADAGE CAPITAL PARTNERS GP, L.L.C.285,3470.01%-4.88%Other
BLACKROCK INC.95,9840.00005%-0.31%Other
GEODE CAPITAL MANAGEMENT, LLC68,7760.00013%22.73%Other
CHANGE IN SHARES OUTSTANDING FOR ANNOVIS BIO INC
STOCK BUYBACKS FOR ANNOVIS BIO INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
0.68%
1Q
09/30/2023
03/31/2023
9.97%
2Q
09/30/2023
12/31/2022
10.39%
3Q
09/30/2023
09/30/2022
10.39%
4Q
09/30/2023
06/30/2022
10.39%
5Q
09/30/2023
03/31/2022
10.48%
6Q
09/30/2023
12/31/2021
11.18%
7Q
09/30/2023
09/30/2021
11.27%
8Q
09/30/2023
06/30/2021
22.34%
9Q
09/30/2023
03/31/2021
30.22%
10Q
09/30/2023
12/31/2020
30.70%
11Q
09/30/2023
09/30/2020
31.15%
12Q
09/30/2023
06/30/2020
31.36%
13Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
0.68%
1Q
03/31/2023
9.97%
2Q
12/31/2022
10.39%
3Q
09/30/2022
10.39%
4Q
06/30/2022
10.39%
5Q
03/31/2022
10.48%
6Q
12/31/2021
11.18%
7Q
09/30/2021
11.27%
8Q
06/30/2021
22.34%
9Q
03/31/2021
30.22%
10Q
12/31/2020
30.70%
11Q
09/30/2020
31.15%
12Q
06/30/2020
31.36%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ANNOVIS BIO INC
LOADING...